GlobeImmune Recruiting for Clinical Trial | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

VX-950 To Get Fast Tracked

Back to News Homepage
Next

MedMira Rapid Test

GlobeImmune Recruiting for Clinical Trial

The Editors at Hepatitis Central
January 9, 2006

Print this page

While GlobeImmune’s therapeutic vaccine for Hepatitis C is only in Phase Ib of clinical trials, their focus on immunity to the Hepatitis C virus is fascinating. GI-5005 is based on tarmogens being potent activators of antigen-specific immune responses against disease.

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Verified by GlobeImmune July 2005
Sponsored by: GlobeImmune
Information provided by: GlobeImmune
ClinicalTrials.gov Identifier: NCT00124215

Purpose:

The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.

Condition Intervention Phase
Hepatitis C Vaccine: GI-5005 Phase I

MedlinePlus related topics: Hepatitis C
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study

Official Title: A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-Center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C Infection

Further study details as provided by GlobeImmune: GI-5005 targets two HCV antigens which are highly conserved, abundant and essential for virus replication. GI-5005 has demonstrated robust activity in preclinical models of HCV. Because the body’s response to Tarmogens resembles successful natural immunity to the hepatitis C virus, the Company believes that the GI-5005 Tarmogen may represent a successful approach to treating this difficult disease. The Company initiated a Phase 1b trial at five US centers for GI-5005 in July 2005.

Expected Total Enrollment: 48
Study start: June 2005

Eligibility:
Ages Eligible for Study: 18 Years and above
Genders Eligible for Study: Both Criteria

Inclusion Criteria:

  • Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy
  • >18 years of age
  • Negative skin test for hypersensitivity to saccharomyces cerevisiae.

Exclusion Criteria:

  • Non-responders to previous interferon treatments
  • Cirrhosis
  • HCV treatment within 3 months
  • Hepatitis B infection
  • HIV infection

Location and Contact Information:

Please refer to this study by ClinicalTrials.gov identifier NCT00124215
John Ferraro 720-859-4134

California
Huntington Medical Research Institutes, Pasadena, California, 91105, United States; Recruiting
Ruth Co 626-397-5825
Myron Tong, M.D., Principal Investigator

Colorado
University of Colorado Health Sciences Center, Denver, Colorado, 80262, United States; Recruiting
Jennifer DeSanto 303-315-1128
Gregory Everson, M.D., Principal Investigator

Florida
University of Miami, Miami, Florida, 33136, United States; Recruiting
Angelique Brown 305-243-2184
Eugene Schiff, M.D., Principal Investigator

Illinois
University of Chicago, Chicago, Illinois, 60637, United States; Recruiting
Katie Wherity 773-702-4477
Helen Te, M.D., Principal Investigator
Donald Jensen, M.D., Sub-Investigator

New York
Weill Medical College of Cornell University, New York City, New York, 10021, United States; Recruiting
Mary Ahern 212-746-2115
Ira Jacobson, M.D., Principal Investigator

More Information:

Sponsor’s website: http://www.globeimmune.com
Study ID Numbers: GI-5005-01
Last Updated: December 8, 2005
Record first received: July 25, 2005
ClinicalTrials.gov Identifier: NCT00124215
Health Authority: United States: Food and Drug Administration

No Comments - be the first!
Share
Share
Previous

VX-950 To Get Fast Tracked

Back to News Homepage
Next

MedMira Rapid Test

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.